PDL BioPharma, Inc. (NASDAQ:PDLI) managed to restrict loss -$0.07 to its price tag before the regular trading session ended on Wednesday, reaching $2.70. PDL BioPharma, Inc. (NASDAQ:PDLI) has seen its stock hit a 1-year low price of $2.15 as well as a 1-year high price of $3.55. Turning to the topic of volume, 2.43 million shares of this company’s common stock changed hands. This organization, at the moment, has a beta score of 0.37, a market cap of $408.98M, and its PE ratio is 3.95. Currently, this public company’s quick ratio is 9.80, its debt-to-equity ratio is 0.14, and its current ratio is 10.00.
Piper Jaffray Resumed shares of PDL BioPharma, Inc. (NASDAQ:PDLI) to a Overweight rating in a report posted on Thursday, December 22nd, 2016. Several additional equities analysts have also published recent reports on PDLI stock. RBC Capital Mkts, for example, Reiterated PDL BioPharma, Inc. to Sector Perform in a report that was made public on Tuesday, February 23rd, 2016. RBC Capital Mkts Reiterated a $5 price target on PDL BioPharma, Inc. in a report from Tuesday, February 2nd, 2016, while giving the stock to a Sector Perform rating. In a report sent out on Thursday, November 5th, 2015, RBC Capital Mkts Reiterated the stock rating on PDL BioPharma, Inc. to a Sector Perform. Lastly, a Sector Perform rating on shares of PDL BioPharma, Inc. was Reiterated by RBC Capital Mkts, which also set a $7 price target on the company’s stock. In total, 1 Wall Street analysts have given this stock a hold rating, with analysts rating it as a strong buy. At the time of writing, this stock has a consensus price target set at $3.00 and average analyst rating set to Hold.
There is a technical analysis indicator called the Relative Strength Index, or RSI, and analysts use it to measure momentum within a range of 0 to 100. When a stock’s RSI falls under 30, it is considered to be oversold. For PDL BioPharma, Inc., specifically, the RSI metric has reached 42.79. PDL BioPharma, Inc. (NASDAQ:PDLI) has lost -10.30% in value over the last three months, and -6.90% over the last six-month period. Over the last full year, the stock price has gained 15.38%.
Moving on to another measurement, let’s talk about volatility: the measurement of a stock’s predictable daily price range. Volatility is essentially the price range where a day trader operates. When volatility is higher, that translates to more extreme losses or profits. After recently verifying the number, PDL BioPharma, Inc. (NASDAQ:PDLI) stock has a volatility measurement of 3.34% for the week, with 3.22% volatility as observed from the past 30 days. The public company has 151.47M shares outstanding currently, as well as a market cap of $408.98M. This stock’s distance from its 20-day simple moving average is -1.64%, based on a recent bid, while its distance from the 50-day simple moving average is currently -6.26%. Meanwhile, it has a distance of -8.00% from the 200-day simple moving average. Today, this organization is sitting -23.92% away from its 52-week high price and 25.58% away from its 52-week low price.
When it comes to more detail-oriented stock traders, they will be keeping their eyes on another measurement – Williams Percent Range or Willams %R. This measurement is a widely-used technical indicator that has its beginnings with Larry Williams, its founder, and it helps us identify when stocks have become oversold or overbought. Highly experienced stock traders will normally use the Williams %R measurement in combination with other trend indicators to pinpoint potential turnaround spots in a stock’s price trajectory. PDL BioPharma, Inc. (NASDAQ:PDLI)’s Williams Percent Range, or 14-day Williams %R, is sitting at 68.97 at the time of writing. Generally speaking, if the indicator rises above -20, the shares may be overbought. On the flip side, if the indicator goes below -80, it may mean that the stock has crossed over into oversold territory.
Investors usually keep their eyes focused on the most recent stock price resistance and support levels. When using the word “support,” we mean the bottom “floor” level where a stock might bounce back after slipping. If the share price can breach the first support level, then overall investor focus may move to the second level. Meanwhile, the resistance is the complete contrary of support levels. As shares grow in price, it may experience a fall as it breaches a particular resistance level. After a recent examination, this company’s shares’ first resistance level is sitting at 2.77. Meanwhile, investors are looking out for the first support level, which is 2.64.